Abstract
This paper analyses the current WTO regulation on patent protection and compulsory licensing, focusing in the access to pharmaceutical products in national emergencies caused by health crisis in countries with insufficient or no manufacturing capacity in the pharmaceutical sector. The applied methodology consists in investigating the provisions of TRIPS Agreement, the DOHA Declaration and the System created with the Decision of August 30, 2003. In that order, the obstacles of the System will be identified; and a solution that
allows an efficient use of the exporting and importing Compulsory Licensing of pharmaceutical products System, will be proposed.
Finally, it will be found that by using the interpretative tools of International Law, alternatives to those obstacles may arise, permitting the System to effectively respond to the humanitarian expectations of developing and less developed countries, as well as to the economic rights of patent holders.
This journal is registered under a Creative Commons Attribution 4.0 International Public License. Thus, this work may be reproduced, distributed, and publicly shared in digital format, as long as the names of the authors and Pontificia Universidad Javeriana are acknowledged. Others are allowed to quote, adapt, transform, auto-archive, republish, and create based on this material, for any purpose (even commercial ones), provided the authorship is duly acknowledged, a link to the original work is provided, and it is specified if changes have been made. Pontificia Universidad Javeriana does not hold the rights of published works and the authors are solely responsible for the contents of their works; they keep the moral, intellectual, privacy, and publicity rights.
Approving the intervention of the work (review, copy-editing, translation, layout) and the following outreach, are granted through an use license and not through an assignment of rights. This means the journal and Pontificia Universidad Javeriana cannot be held responsible for any ethical malpractice by the authors. As a consequence of the protection granted by the use license, the journal is not required to publish recantations or modify information already published, unless the errata stems from the editorial management process. Publishing contents in this journal does not generate royalties for contributors.